{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:14:03Z","timestamp":1794654843537,"version":"4.9.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biopha.2021.112308","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T08:28:33Z","timestamp":1634113713000},"page":"112308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1016","volume":"144","author":[{"given":"Cristina","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ugo Garzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Santarcangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Dacrema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Piccinocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Piccinocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Daglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2021.112308_bib1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.bbagen.2009.07.026","article-title":"Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential","volume":"1790","author":"Shay","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.biopha.2021.112308_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/abbi.1998.1064","article-title":"Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone","volume":"363","author":"Kozlov","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"issue":"12","key":"10.1016\/j.biopha.2021.112308_bib3","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1080\/17425247.2016.1200556","article-title":"Immunomodulatory activities of alpha lipoic acid with a special focus on its efficacy in preventing miscarriage","volume":"13","author":"Monastra","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"10","key":"10.1016\/j.biopha.2021.112308_bib4","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1073\/pnas.0400282101","article-title":"Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid","volume":"101","author":"Suh","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2021.112308_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/pro.5560070125","article-title":"From lipoic acid to multi-enzyme complexes","volume":"7","author":"Reed","year":"1998","journal-title":"Protein Sci.: Publ. Protein Soc."},{"issue":"8","key":"10.1016\/j.biopha.2021.112308_bib6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/biom9080356","article-title":"Insights on the use of alpha-lipoic acid for therapeutic purposes","volume":"9","author":"Salehi","year":"2019","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.pain.2007.01.011","article-title":"Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorylation in animal models of pain","volume":"131","author":"Gao","year":"2007","journal-title":"Pain"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.112308_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pain.2006.01.013","article-title":"Analgesic effect of vitamin E is mediated by reducing central sensitization in neuropathic pain","volume":"122","author":"Kim","year":"2006","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.biopha.2021.112308_bib9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.freeradbiomed.2011.01.026","article-title":"Roles of reactive oxygen and nitrogen species in pain","volume":"51","author":"Salvemini","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/jpet.103.064154","article-title":"A newly identified role for superoxide in inflammatory pain","volume":"309","author":"Wang","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.biopha.2021.112308_bib11","first-page":"4219","article-title":"Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study","volume":"21","author":"Parente","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2021.112308_bib12","series-title":"Classification of Chronic Pain","first-page":"209","article-title":"Part III: pain terms, a current list with definitions and notes on usage","year":"1994"},{"issue":"5","key":"10.1016\/j.biopha.2021.112308_bib13","first-page":"659","article-title":"Alpha lipoic acid and superoxide dismutase in the treatment of chronic low back pain","volume":"49","author":"Battisti","year":"2013","journal-title":"Eur. J. Phys. Rehabil. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/jmf.2017.0068","article-title":"Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: a 6-month exploratory study","volume":"21","author":"Cavestro","year":"2018","journal-title":"J. Med. Food"},{"issue":"5","key":"10.1016\/j.biopha.2021.112308_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/jmf.2017.0056","article-title":"Effect of alpha-lipoic acid on clinical and neurophysiologic recovery of carpal tunnel syndrome: a double-blind, randomized clinical trial","volume":"21","author":"Monroy Guizar","year":"2018","journal-title":"J. Med. Food"},{"issue":"5","key":"10.1016\/j.biopha.2021.112308_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1034\/j.1600-0714.2002.310503.x","article-title":"Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy","volume":"31","author":"Femiano","year":"2002","journal-title":"J. Oral. Pathol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2337\/diacare.26.3.770","article-title":"The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial","volume":"26","author":"Ametov","year":"2003","journal-title":"Diabetes Care"},{"issue":"3\u20134","key":"10.1016\/j.biopha.2021.112308_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0891-5849(99)00089-1","article-title":"Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial","volume":"27","author":"Jacob","year":"1999","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10715769900300721","article-title":"Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy","volume":"31","author":"Reljanovic","year":"1999","journal-title":"Free Radic. Res."},{"issue":"12","key":"10.1016\/j.biopha.2021.112308_bib20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1046\/j.1464-5491.1999.00190.x","article-title":"Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy","volume":"16","author":"Ruhnau","year":"1999","journal-title":"Diabet. Med.: J. Br. Diabet. Assoc."},{"issue":"2","key":"10.1016\/j.biopha.2021.112308_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/1352458505ms1143oa","article-title":"Lipoic acid in multiple sclerosis: a pilot study","volume":"11","author":"Yadav","year":"2005","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.biopha.2021.112308_bib22","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.biopha.2021.112308_bib23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/diacare.20.3.369","article-title":"Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie","volume":"20","author":"Ziegler","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2021.112308_bib25","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/OPTH.S115900","article-title":"Tolerability in the elderly population of high-dose alpha lipoic acid: a potential antioxidant therapy for the eye","volume":"10","author":"Sarezky","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2021.112308_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2147\/DMSO.S219438","article-title":"Insulin Autoimmune Syndrome (Hirata Disease): a comprehensive review fifty years after its first description","volume":"13","author":"Cappellani","year":"2020","journal-title":"Diabetes, Metab. Syndr. Obes.: Targets Ther."},{"issue":"1","key":"10.1016\/j.biopha.2021.112308_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40618-016-0536-3","article-title":"The treatment of hyperinsulinemic hypoglycaemia in adults: an update","volume":"40","author":"Davi","year":"2017","journal-title":"J. Endocrinol. Investig."},{"issue":"17","key":"10.1016\/j.biopha.2021.112308_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/atm.2018.07.32","article-title":"Insulin autoimmune syndrome: from diagnosis to clinical management","volume":"6","author":"Censi","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112308_bib29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1139\/cjpp-2014-0353","article-title":"Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes","volume":"93","author":"Rochette","year":"2015","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112308_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/bja\/aen103","article-title":"Assessment of pain","volume":"101","author":"Breivik","year":"2008","journal-title":"Br. J. Anaesth."},{"issue":"2","key":"10.1016\/j.biopha.2021.112308_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrar","year":"2000","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.biopha.2021.112308_bib33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","article-title":"Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain","volume":"4","author":"Jensen","year":"2003","journal-title":"J. Pain"},{"key":"10.1016\/j.biopha.2021.112308_bib34","unstructured":"CareCloud, ICD-10 CODE: M25.50 \u2013 PAIN IN UNSPECIFIED JOINT. \u3008https:\/\/www.carecloud.com\/icd-10-codes\/m25\u201350\/\u3009 (Accessed 8 February 2021)."},{"key":"10.1016\/j.biopha.2021.112308_bib35","unstructured":"ICD9Data.com, ICD-9-CM Diagnosis Code 719.4, 2015. \u3008http:\/\/www.icd9data.com\/2015\/Volume1\/710\u2013739\/710\u2013719\/719\/719.4.htm?__hstc=93424706.c035ccd7516941e061fc3347b6766cd2.1627322603670.1627322603670.1627322603670.1&__hssc=93424706.21.1627322603671&__hsfp=1360741907-\u3009 (Accessed 8 Febrauary 2021)."},{"issue":"8","key":"10.1016\/j.biopha.2021.112308_bib36","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2021.112308_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00296-016-3481-8","article-title":"An overview of treatment approaches for chronic pain management","volume":"37","author":"Hylands-White","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.biopha.2021.112308_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ajem.2018.01.008","article-title":"A systematic review of the pain scales in adults: which to use?","volume":"36","author":"Karcioglu","year":"2018","journal-title":"Am. J. Emerg. Med."},{"issue":"7","key":"10.1016\/j.biopha.2021.112308_bib39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","article-title":"Pain: a review of three commonly used pain rating scales","volume":"14","author":"Williamson","year":"2005","journal-title":"J. Clin. Nurs."},{"issue":"4","key":"10.1016\/j.biopha.2021.112308_bib40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur. J. Pain"},{"issue":"1","key":"10.1016\/j.biopha.2021.112308_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.biopha.2021.112308_bib42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/mus.24969","article-title":"Causes of neuropathy in patients referred as \u201cidiopathic neuropathy\u201d","volume":"53","author":"Farhad","year":"2016","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.biopha.2021.112308_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdi.13401","article-title":"Current concepts in the management of diabetic polyneuropathy","volume":"12","author":"Ziegler","year":"2021","journal-title":"J. Diabetes Investig."},{"issue":"37","key":"10.1016\/j.biopha.2021.112308_bib44","first-page":"616","article-title":"The pharmacological therapy of chronic neuropathic pain","volume":"113","author":"Binder","year":"2016","journal-title":"Dtsch. Arzteblatt Int."},{"key":"10.1016\/j.biopha.2021.112308_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fneur.2017.00307","article-title":"Adverse effects of antidepressants for chronic pain: a systematic review and meta-analysis","volume":"8","author":"Riediger","year":"2017","journal-title":"Front. Neurol."},{"issue":"Suppl A","key":"10.1016\/j.biopha.2021.112308_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/eujp.2001.0324","article-title":"Anticonvulsants in neuropathic pain: rationale and clinical evidence","volume":"6","author":"Jensen","year":"2002","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.biopha.2021.112308_bib47","series-title":"Acetaminophen Toxicity","author":"Agrawal","year":"2021"},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib48","first-page":"297","article-title":"Extrahepatic toxicity of acetaminophen: critical evaluation of the evidence and proposed mechanisms","volume":"3","author":"Kennon-McGill","year":"2018","journal-title":"J. Clin. Transl. Res."},{"key":"10.1016\/j.biopha.2021.112308_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.684162","article-title":"Pharmacogenomics of NSAID-induced upper gastrointestinal toxicity","volume":"12","author":"McEvoy","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112308_bib50","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1039\/C9FO00390H","article-title":"Metabolic effects of alpha-lipoic acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study","volume":"10","author":"Gosselin","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.biopha.2021.112308_bib51","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.2147\/DDDT.S280802","article-title":"Safety and efficacy of alpha lipoic acid during 4 years of observation: a retrospective, clinical trial in healthy subjects in primary prevention","volume":"14","author":"Derosa","year":"2020","journal-title":"Drug Des., Dev. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib52","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.clnu.2020.07.028","article-title":"Assessment of adverse reactions to alpha-lipoic acid containing dietary supplements through spontaneous reporting systems","volume":"40","author":"Gatti","year":"2021","journal-title":"Clin. Nutr."},{"issue":"2","key":"10.1016\/j.biopha.2021.112308_bib53","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.clnu.2020.12.003","article-title":"Interpreting data on alpha-lipoic acid safety considering the number of subjects exposed","volume":"40","author":"Favari","year":"2021","journal-title":"Clin. Nutr."},{"issue":"10","key":"10.1016\/j.biopha.2021.112308_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9101011","article-title":"Safety evaluation of alpha-lipoic acid supplementation: a systematic review and meta-analysis of randomized placebo-controlled clinical studies","volume":"9","author":"Fogacci","year":"2020","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.biopha.2021.112308_bib55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/jdi.13180","article-title":"Nationwide survey of endogenous hyperinsulinemic hypoglycemia in Japan (2017-2018): Congenital hyperinsulinism, insulinoma, non-insulinoma pancreatogenous hypoglycemia syndrome and insulin autoimmune syndrome (Hirata\u2019s disease)","volume":"11","author":"Yamada","year":"2020","journal-title":"J. Diabetes Investig."},{"issue":"6","key":"10.1016\/j.biopha.2021.112308_bib56","article-title":"Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome","volume":"19","author":"Turck","year":"2021","journal-title":"EFSA J. Eur. Food Saf. Auth."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:35:14Z","timestamp":1760099714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221010921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":56,"alternative-id":["S0753332221010921"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112308","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112308"}}